Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema

OBJECTIVE: Patients with diabetic macular oedema (DME) are known to have significantly greater medical treatment burden than patients with non-DME. Frequent injections and office visits can have a substantial impact on patient adherence and quality of life. This analysis assesses the impact of the 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Matthew, Osher, James, Riemann, Christopher D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254114/
https://www.ncbi.nlm.nih.gov/pubmed/32518834
http://dx.doi.org/10.1136/bmjophth-2019-000416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254114/
https://www.ncbi.nlm.nih.gov/pubmed/32518834
http://dx.doi.org/10.1136/bmjophth-2019-000416

Ejemplares similares